Vanda Pharmaceuticals Inc. 8-K Report: Stock Structure Insights & Investor Updates

The provided section of the financial report contains the following key information regarding Vanda Pharmaceuticals Inc.:

1. Company Identification:

• Name: Vanda Pharmaceuticals Inc.
• CIK (Central Index Key): 0001347178
• SEC File Number: 001-34186
• Tax ID: 03-0491827
• Address: 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037
• Contact Number: 202-734-3400

2. Filing Type:

• Form: 8-K (a report of unscheduled material events or corporate changes)

3. Reporting Date:

• Date of Report: February 13, 2025

4. Stock Information:

• Common Stock:
• • Par Value: $0.001 per share
  • Ticker Symbol: VNDA
  • Exchange: NASDAQ
• Series A Junior Participating Preferred Stock Purchase Right:
• • Par Value: $0.001 per share

5. Contextual Segment Information:

• The report includes details about different classes of stock, specifically:
• • Common Stock
  • Series A Junior Participating Preferred Stock Purchase Right

6. XML Namespace and Schema:

• The report is structured in XBRL (eXtensible Business Reporting Language), indicating compliance with SEC filing requirements for structured financial data.

Insights:

• The form indicates that Vanda Pharmaceuticals is actively updating investors about corporate developments, which is essential for transparency and investor relations.
• The presence of both common stock and preferred stock purchase rights suggests a capital structure that may appeal to different types of investors, potentially enhancing the company's financial flexibility.
• The reporting date in 2025 indicates that this document is part of future planning or notifications, which may pertain to upcoming corporate actions or changes in the company’s structure.

Overall, this report highlights the essentials of Vanda Pharmaceuticals’ stock structure and compliance with SEC regulations, important for stakeholders assessing the company's financial health and governance.